Molecular origin of polyglutamine aggregation in neurodegenerative diseases

被引:83
|
作者
Khare, SD
Ding, F
Gwanmesia, KN
Dokholyan, NV [1 ]
机构
[1] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA
[2] Delaware State Univ, Dept Phys & Preengn, Delaware, OH USA
关键词
D O I
10.1371/journal.pcbi.0010030
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Expansion of polyglutamine (polyQ) tracts in proteins results in protein aggregation and is associated with cell death in at least nine neuroclegenerative diseases. Disease age of onset is correlated with the polyQ insert length above a critical value of 35-40 glutamines. The aggregation kinetics of isolated polyQ peptides in vitro also shows a similar critical-length dependence. While recent experimental work has provided considerable insights into polyQ aggregation, the molecular mechanism of aggregation is not well understood. Here, using computer simulations of isolated polyQ peptides, we show that a mechanism of aggregation is the conformational transition in a single polyQ peptide chain from random coil to a parallel P-helix. This transition occurs selectively in peptides longer than 37 glutamines. in the P-helices observed in simulations, all residues adopt P-strand backbone dihedral angles, and the polypeptide chain coils around a central helical axis with 18.5 +/- 2 residues per turn. We also find that mutant polyQ peptides with proline-glycine inserts show formation of antiparallel beta-hairpins in their ground state, in agreement with experiments. The lower stability of mutant P-helices explains their lower aggregation rates compared to wild type. Our results provide a molecular mechanism for polyQ-mediated aggregation.
引用
收藏
页码:230 / 235
页数:6
相关论文
共 50 条
  • [1] Huntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases
    Truant, Ray
    Atwal, Randy Singh
    Desmond, Carly
    Munsie, Lise
    Tran, Thu
    FEBS JOURNAL, 2008, 275 (17) : 4252 - 4262
  • [2] Polyglutamine expansions and neurodegenerative diseases
    Saudou, F
    Devys, D
    Trottier, Y
    Imbert, G
    Stoeckel, ME
    Brice, A
    Mandel, JL
    GENETIC AND PSYCHIATRIC DISORDERS, 1998, 69 : 261 - 277
  • [3] Polyglutamine expansions and neurodegenerative diseases
    Saudou, F
    Devys, D
    Trottier, Y
    Imbert, G
    Stoeckel, ME
    Brice, A
    Mandel, JL
    COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, 1996, 61 : 639 - 647
  • [4] Polyglutamine Repeats in Neurodegenerative Diseases
    Lieberman, Andrew P.
    Shakkottai, Vikram G.
    Albin, Roger L.
    ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 14, 2019, 14 : 1 - 27
  • [5] RNA therapy for polyglutamine neurodegenerative diseases
    Watson, Lauren M.
    Wood, Matthew J. A.
    EXPERT REVIEWS IN MOLECULAR MEDICINE, 2012, 14
  • [6] Polyglutamine diseases: looking beyond the neurodegenerative universe
    Michal Mielcarek
    Mark Isalan
    Neural Regeneration Research, 2021, 16 (06) : 1186 - 1187
  • [7] Polyglutamine diseases: looking beyond the neurodegenerative universe
    Mielcarek, Michal
    Isalan, Mark
    NEURAL REGENERATION RESEARCH, 2021, 16 (06) : 1186 - 1187
  • [8] MOLECULAR PATHWAYS TO POLYGLUTAMINE AGGREGATION
    Robertson, Amy L.
    Bottomley, Stephen P.
    TANDEM REPEAT POLYMORPHISMS: GENETIC PLASTICITY, NEURAL DIVERSITY AND DISEASE, 2012, 769 : 115 - 124
  • [9] POLYGLUTAMINE AGGREGATION IN HUNTINGTON AND RELATED DISEASES
    Polling, Saskia
    Hill, Andrew F.
    Hatters, Danny M.
    TANDEM REPEAT POLYMORPHISMS: GENETIC PLASTICITY, NEURAL DIVERSITY AND DISEASE, 2012, 769 : 125 - 140
  • [10] Polyglutamine diseases: protein cleavage and aggregation
    Zoghbi, HY
    Orr, HT
    CURRENT OPINION IN NEUROBIOLOGY, 1999, 9 (05) : 566 - 570